The IMID Forum

Join Doctor Sofia Ramiro and Professor Phillip Mease as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2026

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Ibis et al. and Russell et al. which explore how targeted therapies may improve outcomes in patients with RA.

Join Professor Peter Nash from Griffith University in Brisbane and Doctor Mark Gibson from the Centre for Rheumatic Diseases, King’s College London, as they discuss Doctor Gibson’s recent paper, ‘Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs’.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review paper by Bechman et al. where he highlights the impact of BMI on response to JAK inhibitors in RA.

Join Dr Sofia Ramiro and Dr Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered whether men and women with axSpA respond differently to bimekizumab, using 52-week data from the BE MOBILE 1 and 2 trials, covering both non-radiographic and radiographic axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor van Mulligen, from the Department of Rheumatology, Leiden University Medical Centre, as they discuss her recent paper ‘Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibodynegative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Finckh et al. and Charles‑Schoeman et al, in which authors the impact of shared epitope positivity on bDMARD effectiveness and compare treatment persistence and switching to UPA versus other advanced therapies after TNFi failure.

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in PsA. This month’s conversation explores recent advances in PsA and immune-mediated inflammatory disease therapies.

Join Professor Peter Nash from the Griffith University in Brisbane; Professor Axel Finckh, from the Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland; and Bente Glintborg, an Associate Professor from the Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark as they discuss his recent paper ‘Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis’.

Join Professor Iain McInnes and Doctor Philip Mease for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they examine key findings from studies by Fleischmann et al. and Nozaki et al. discussing the long-term effectiveness and safety of advanced targeted therapies for RA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Murat Torgutalp, from the Charité – Universitätsmedizin in Berlin, as they discuss his recent paper ‘Frequency and characteristics of axial involvement in psoriatic arthritis: Results from the International Multicentre AXIS Study’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two recent studies by Etani et al. and George et al. that examine the infectious complications associated with immunosuppressive therapy in rheumatoid arthritis, including herpes zoster risk across five JAK inhibitors and the relationship between RA treatments and nonserious infections.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Chung-Mao Kao from Taichung Veterans General Hospital, as they discuss the recent publication ‘Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A 5-year population-based cohort study’.

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in psoriatic arthritis. This month’s conversation explores how patients with differing levels of baseline disease activity may require different degrees of improvement before perceiving treatment benefit, highlighting the potential for more personalised treatment targets and shared decision making in PsA.

Join Professors Xenofon Baraliakos, Laura Coates and Dr Sofia Ramiro as they break down the top RA, PsA and axSpA abstracts, sessions and posters from this year's EULAR conference.

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 2 of EULAR 2026 (Thursday, June 4th).

Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 1 of EULAR 2026 (Wednesday, June 3rd).

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Mysler et al. and Taylor et al, in which authors explore how different treatment strategies may improve outcomes in patients with RA.

Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensus.

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘safety and clinical efficacy of bimekizumab in patients with active PsA who were bDMARD-naïve or TNFi-IR, and the second provided a comprehensive and updated overview of bimekizumab’s safety profile to support clinical decision-making.

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.

Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA.

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Strand et al. that evaluated TOF efficacy, safety, and persistence by sex, and explored whether age-related factors contribute to differences in treatment response between males and females, and by Alten et al. that explored the long‑term effectiveness of baricitinib and other b/tsDMARDs in patients with RA with early low disease activity or remission.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients...